Long‐term follow‐up after proton beam therapy for pediatric tumors: a Japanese national survey

@article{Mizumoto2017LongtermFA,
  title={Long‐term follow‐up after proton beam therapy for pediatric tumors: a Japanese national survey},
  author={M. Mizumoto and S. Murayama and T. Akimoto and Y. Demizu and T. Fukushima and Y. Ishida and Y. Oshiro and Haruko Numajiri and H. Fuji and T. Okumura and H. Shirato and H. Sakurai},
  journal={Cancer Science},
  year={2017},
  volume={108},
  pages={444 - 447}
}
Proton beam therapy (PBT) is a potential new alternative to treatment with photon radiotherapy that may reduce the risk of late toxicity and secondary cancer, especially for pediatric tumors. The goal of this study was to evaluate the long‐term benefits of PBT in cancer survivors. A retrospective observational study of pediatric patients who received PBT was performed at four institutions in Japan. Of 343 patients, 62 were followed up for 5 or more years. These patients included 40 males and 22… Expand
Photon or Proton Therapy for Adolescent and Young Adult Tumors Focused on Long-Term Survivors
TLDR
This study is one of the largest studies to focus on life after radiation therapy among AYAs and suggests that cancer treatment has an influence on life events. Expand
Preliminary Result of Hyperfractionated High-Dose Proton Beam Radiotherapy for Pediatric Skull Base Chordomas
TLDR
Proton beam therapy (PBT) may provide good local control for skull base chordoma and reduced toxicities, especially for pediatric patients, and overall findings indicate that hyperfractionated high-dose PBT is safe and effective foriatric patients with skullbase chordoma. Expand
Preliminary results of proton radiotherapy for pediatric rhabdomyosarcoma: a multi‐institutional study in Japan
TLDR
Proton radiotherapy has the same treatment effect as photon radiotherapy with tolerable acute radiation‐induced toxicity, and is recommended for pediatric patients with rhabdomyosarcoma. Expand
Long-Term Follow-up of Patients Treated at a Single Institution Using a Passively Scattered Proton Beam; Observations Around the Occurrence of Second Malignancies.
TLDR
For out-of-field SMs, no increased risk of developing a variety of malignancies was observed and only 1 malignant histology was noted 15 years after the original proton therapy. Expand
An Analysis of Vertebral Body Growth after Proton Beam Therapy for Pediatric Cancer
TLDR
The results suggest that the growth rate of the vertebral body is dose-dependent and decreases even at a low irradiated dose, which indicates the need for careful planning of the irradiation area in this patient population. Expand
Proton beam therapy for adolescent primary central nervous system lymphoma with residual tumor after intensive chemotherapy: a case report.
TLDR
An adolescent patient with PCNSL exhibiting 4 of 5 adverse prognostic factors at diagnosis and a residual tumor adjacent to the pituitary gland with gadolinium enhancement on brain magnetic resonance imaging is encountered, and local PBT is selected as a salvage treatment for the residual tumor. Expand
Current status of proton therapy outcome for paediatric cancers of the central nervous system - Analysis of the published literature.
TLDR
Proton therapy for the treatment of paediatric cancers of the central nervous system was found to provide survival and tumour control outcomes comparable to photon therapy, and reduced incidence of severe acute and late toxicities was reported. Expand
Evolving Radiotherapy Techniques in Paediatric Oncology.
TLDR
The development of radiotherapy techniques is beneficial for children in terms of reducing dose exposure and proton therapy may achieve high survival rates and tumour control rates while decreasing the risk for side-effects. Expand
The first pediatric case of sacral Ewing sarcoma treated with space‐making particle therapy
TLDR
A pediatric case of sacral Ewing sarcoma treated with space-making particle therapy (SMPT) using a novel bioabsorbable spacer made of polyglycolic acid (PGA) surgical sutures was reported. Expand
Proton Beam Therapy for Pediatric Brain Tumor
TLDR
Proton beam therapy (PBT) is a particle radiotherapy with excellent dose localization that permits treatment of liver and lung cancer by administration of a high dose to the tumor while minimizing damage to surrounding normal tissues and has the potential advantages for pediatric cancer. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 20 REFERENCES
Proton beam therapy for pediatric malignancies: a retrospective observational multicenter study in Japan
TLDR
Preliminary results for PBT in pediatric patients in Japan are provided, suggesting reduced secondary cancer and other late toxicities after proton beam therapy (PBT) due to dosimetric advantages are a concern in long‐term survivors. Expand
Long-term side effects of radiotherapy for pediatric localized neuroblastoma
TLDR
After a median follow-up of 14 years, late effects with multimodality treatment were frequent and the most frequent effects were musculoskeletal abnormalities and the threshold for their occurrence was 31 Gy. Expand
Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma.
  • M. Ladra, J. Szymonifka, +9 authors T. Yock
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014
TLDR
Five-year LC, EFS, and OS rates were similar to those observed in comparable trials that used photon radiation and proton radiation appears to represent a safe and effective radiation modality for pediatric RMS. Expand
Proton radiotherapy for pediatric bladder/prostate rhabdomyosarcoma: clinical outcomes and dosimetry compared to intensity-modulated radiation therapy.
TLDR
This study provides evidence of significant dose savings to normal structures with proton radiotherapy compared to IMRT and is well tolerated in this patient population. Expand
Comparison of second cancer risk due to out-of-field doses from 6-MV IMRT and proton therapy based on 6 pediatric patient treatment plans.
  • B. Athar, H. Paganetti
  • Medicine
  • Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 2011
TLDR
In terms of out-of-field risks, IMRT offers advantage close to the primary field and an increasing advantage for passive proton therapy is noticed with increasing distance to the field, and scanning proton beam therapy shows the lowest risks. Expand
Adverse events of local treatment in long-term head and neck rhabdomyosarcoma survivors after external beam radiotherapy or AMORE treatment.
TLDR
This study may serve as a baseline inventory and can be used in future studies for prospective assessments of AEs following the introduction of novel local treatment modalities. Expand
Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma.
TLDR
Late effects of treatment in children receiving radiotherapy for head and neck rhabdomyosarcoma are frequent and hearing loss was thought to be a direct result of tumor destruction and, in 1 case, cisplatin chemotherapy. Expand
Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer.
TLDR
Proton therapy can reduce the risk of an SMN in prostate patients compared with contemporary IMRT, and the risks from the in-field organs were considerably lower with the proton therapy plan than with the IMRT plan. Expand
Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects.
TLDR
Proton radiotherapy for patients with PM-RMS yields tumor control and survival comparable to that in historical controls with similar poor prognostic factors, and rates of late effects from proton radi therapy compare favorably to published reports of photon-treated cohorts. Expand
A dosimetric comparison of proton and intensity-modulated photon radiotherapy for pediatric parameningeal rhabdomyosarcomas.
TLDR
For pediatric PRMS, superior normal tissue sparing is achieved with proton radiation therapy compared with IMRT because of enhanced conformality, proton plans also demonstrate greater normal tissue dose distribution asymmetry. Expand
...
1
2
...